title: [Drug hypersensitive syndrome caused by fluindione].
abstract: BACKGROUND
  Fluindione (Previscan) is an oral anticoagulant prescribed in relay to heparin therapy for deep venous thrombosis, pulmonary embolism... The main complications with oral anticoagulants are bleeding. However, severe immuno-allergic complications, especially acute hepatitis, acute renal failure and acute bone marrow failure, have been described with phenindione therapy.
  
  
  METHODS
  The authors report herein the first five cases of drug-induced hypersensitivity syndrome due to fluindione. Clinical signs included erythroderma and severe systemic manifestations which occurred within 3 to 8 weeks after introducing the molecule. Sex ratio was four males for one female; their ages ranged from 53 to 84 years. Clinical signs included erythroderma (with photosensitivity in two patients), lymphadenopathy and fever evoking severe sepsis. In our observations, marked eosinophilia (5 cases), lymphocytosis, atypical lymphocytes (4 cases), hepatic cytolysis (4 cases), associated in 2 cases with hepatic cholestasis, and pulmonary signs were noted. Cutaneous eruption healed in about 3 to 6 weeks after withdrawal of the drug. In two cases, systemic steroids were required for the severity of systemic manifestations. Long after the acute episode and when steroids were stopped, patch testing with fluindione was still positive.
  
  
  CONCLUSIONS
  To date, acute and/or severe skin diseases due to fluindione, associated or not with multisystemic involvement, have never been reported. This molecule is the most commonly used for the treatment of thromboembolic diseases. Patch testing is easy to perform and can help physicians find the responsible molecule. Moreover, skin manifestations are present only in 87 p. 100 of drug-induced hypersensitivity syndromes. Acute hepatitis and acute renal failure might be drug-induced hypersensitivity syndromes without cutaneous manifestations.
authors.affiliation: Service de Dermatologie et Vénéréologie, Hôpital Dupuytren, CHRU, Limoges.
authors.forename: A
authors.initials: A
authors.lastname: Sparsa
authors.forename: C
authors.initials: C
authors.lastname: Bédane
authors.forename: H
authors.initials: H
authors.lastname: Benazahary
authors.forename: P
authors.initials: P
authors.lastname: De Vencay
authors.forename: M L
authors.initials: ML
authors.lastname: Gauthier
authors.forename: V
authors.initials: V
authors.lastname: Le Brun
authors.forename: S
authors.initials: S
authors.lastname: Boulinguez
authors.forename: V
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: P
authors.initials: P
authors.lastname: Soria
authors.forename: E
authors.initials: E
authors.lastname: Vidal
authors.forename: J M
authors.initials: JM
authors.lastname: Bonnetblanc
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010630:Phenindione / Q000009:adverse effects* / Q000031:analogs & derivatives*; D013577:Syndrome
chemical_list: D000925:Anticoagulants; D010630:Phenindione; C017673:fluindione